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Table 1   Clinical and laboratory findings at the time of diagnosis
Feature           DS-AMKL non-DS-AMKL                 P 
(n=24)                              (n=21)
Median age, mo (range) 21 (8-38)        15 (2-185)   0.52
Sex
M/F ratio 12:12      8:13  0.42
Clinical findings 
Fever, no. (%) 12 (50)         14 (67)  0.33
Lymphadenopathy, no. (%) 2 (8.3)         6 (29) 0.12
Hepatomegaly, no. (%) 16 (67)         14 (67)  1.00
Splenomegaly, no. (%) 11 (46)        9 (43)  1.00
Laboratory findings 
Hemoglobin, g/dL (median, range) 8.3 (5.2-13.0)  8.2 (3.6-11.0) 0.38
Platelets, ×109/L (median, range) 26.0 (2-143)      24.0 (3-492) 0.72
Leukocytes, ×109/L (median, range) 6.8 (2.4-107.0) 17.9 (0.1-134.8) 0.07
Circulating blast cells, % (median, range) 15.0 (0-88)        13.0 (0-82)     0.95
Bone marrow blast cells, % (median, range) 25.0 (2-90)        50.0 (10-81) 0.09
Serum LDH, IU/L (median, range) 662 (260-6450) 1639 (338-8660) 0.11
Abbreviations: DS-AMKL, Down syndrome-associated acute megakaryoblastic leukemia; LDH, lactic dehydrogenase.
Table  2 Morphological classification, immunophenotype and karyotype of the 24 patients with DS-AMKL
Patient          Age            Sex     Morphological Immunophenotype (%) Karyotype
No.         (months)                    classification     CD7    CD13   CD36   CD41   CD42   GlyA
A: Constitutional trisomy 21 only
1 32 F 3+Tri 57 19 42 10 14 NA 47,XX,+21c
2 21 F 1A 68 36 42 12 NA 13 47,XX,+21c
3 21 M 2B 72 17 55 56 NA 20 47,XY,+21c
4 21 F 3+Ep 18 45 NA 31 44 NA 47,XX,+21c
5 18 M 2B 53 78 81 43 47 24 47,XY,+21c 
B: Numerical abnormalities only
6 21 M 1A 83 20 NA 41 42 2 51,XY,+8,+19,+21c,+21,+22
7 8 M 1A 56 10 NA 16 23 NA 48,XY,+8,+21c 
C: −5/del(5q) and/or −7/del(7q)
8 20 F 1B 78 30 35 24 34 NA 47,XX,del(6)(q23q25),-7,+ring(7?),+21c 
9 23 F 1A 36 29 83 76 75 NA 46,XX,-1,+der(1)t(1;?),-5,+der(5)t(5;7),-7,+21c
10 24 F 1A+dE 90 30 35 24 34 NA 47,XX,del(7)(q32),+21c
11 17 F 3+m 40 75 NA 14 12 12 47,XX,add(5)(p15),-7,+8,+21c
12 20 F 2B 14 79 NA 4 25 99 90,idem×2,-3,-7,-9,del(11)(q?),-18
13 38 M 2B+dE 81 83 NA 15 20 4 47,XY,-7,+8,+21c,+rl
D: Other structural changes
14 20 F 1A 83 27 NA 59 87 NA 48,X,der(X)t(X;1)(q28;q25),+11,+21c
15 18 M 1A 70 12 34 2 2 38 47,XY,der(3)t(3;3)(p25;p10),i(7q),
der(17)t(1;17)(q25;q25),+21c
16 17 F 1A 51 4 NA 11 9 28 48,idem,add(5)(q1?),+11
17 12 M 1A 89 36 NA 74 19 15 47,XY,der(7)t(1;7)(q23;q36),del(20)(q11q13.1),+21c
18 29 M 2B 60 43 69 14 34 62 47,XY,del(11)(p?),+21c
19 25 F 1A+dE 71 23 NA 41 NA 84 47,XX,t(5;12)(p15;q21),add(7)(p11),+21c,add(22)(q13)
20 18 M 1B 52 37 NT 10 26 32 48,idem,+add21
21 22 F 1B+Ep 99 78 88 59 66 93 47,XX,add(7)(p11),add(19)(p13),+21c
22 8 M 1A 72 53 64 72 75 4 NA
23 21 M 2A 87 12 33 20 23 4 NA
24 19 F 1A 87 26 NA 40 NA 11 NA
Abbreviations: GlyA indicates glycophorin A; Tri, trilineage dysplasia; NA, not available; Ep, emperipolesis; dE, dyserythropoieis; m, micromegakaryocytes.
A: Normal karyotypes
1 147 F 3+m 66 95 42 53 19 1 46,XX 
2 18 M 2A+Tri 25 54 40 4 2 4 46,XY
B: Numerical abnormalities only
3 3 F NA 1 88 NA 77 54 8 48,XX,+21,+22
4 15 F 2A 42 9 NA 68 10 NA 58,XX,+X,+2,+2,+6,+7,+8,+10,+13,+15,+19,+19,+22
5 38 F 1A 38 30 NA 10 4 NA 49,XX,+12,+18,+22 
6 12 F NA NA 30 NA 95 NA NA 57,XX,+2,+4,+6,+7,+8,+10,+14,+15,+19,+19,+22
7 45 M 1A 95 3 NA 86 3 1 48,idem,+8
8 2 M 2A 19 32 NA 46 18 5 51,XY,+6,+7,+8,+19,+21
C: t(1;22)(p13;q13)
9 2 F 2A+dE NA NA NA NA NA NA 46,XX,t(1;22)(p13;q13)
10 12 M 1A 5 13 NA 67 70 NA 51,XY,+der(1)t(1;22)(p13; q13),t(1;22)(p13;q13),
+6,+7,+10,+19
D: 3q21q26 abnormalities
11 12 M 1A 14 3 64 48 47 NA 46,XY,-11,der(11)t(3;11)(q21;p15)
E: t(16;21)(p11;q22)
12 38 M 3+Ep 3 69 NA 33 33 NA 46,XY,t(16;21)(p11;q22) 
F: −7
13 8 F 1A 30 7 NA 82 80 NA 46,XX,-7,-7,del(11)(p11),+2mar,inc
14 41 M 3+m 66 43 NA 28 32 8 47,XY,-7,+21,+ring(1)
G: Other structural changes
15 7 M 1A 12 65 NA 57 NA NA 46,XY,t(2;7)(p12;p22)
16 28 F 1A NA NA NA 30 17 1 51,XX,+X,6p+,6p+,-13,+21,+21,+2mar
17 35 F 3+m 3 18 2 78 1 NA 47,XX,add(16)(p13),+21 
18 12 F 2A+dE 30 5 62 67 55 5 46,XX,t(2;11;19)(q31;q13;q13.4),del(3)(q23),13q-
19 6 F NA NA 10 NA 52 53 NA 51,XX,4p+,11q+,14q+,+17,+19,+21,+22 ,+mar
20 33 F 2A 5 2 12 5 1 1 46,XX,del(2)(q11),del(2)(q31),der(5)t(2;5)(q11;q22),
der(5)t(5;13)(q35;q14),-13,add(16)(p13),+mar
21 185 F 2A 59 90 NA 16 4 NA 49,XX,+5,+8,i(17)(q10),+21
Table  3 Morphological classification, immunophenotype and karyotype of the 21 patients with non-DS-AMKL
Patient       Age            Sex     Morphological Immunophenotype (%)         Karyotype
No.      (months)                  classification      CD7 CD13   CD36   CD41   CD42   GlyA
Abbreviations: GlyA indicates glycophorin A; Tri, trilineage dysplasia; NA, not available; Ep, emperipolesis; dE, dyserythropoieis; m, micromegakaryocytes.
